# uniQure N.V. (QURE) · Edgar & Edgarette company card

> uniQure N.V. (QURE) saw revenue fall 40.6% in FY2025 to $16 million, operating margin -1151% against a -3.8% median for pharmaceutical preparations, equity 24.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1590560 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/QURE) · [JSON](https://www.pops4.com/boards/company/QURE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $16M |
| Revenue growth, 1 year | -40.6% |
| Revenue growth per year | -58.1% |
| Operating margin | -1151.4% (prior year -679.6%) |
| Net margin | -1236.0% |
| Operating cash flow | −$178M |
| Capital spending | $439,000 |
| Free cash flow | −$178M |
| Cash | $80M |
| Long-term debt | $72M |
| Total assets | $825M |
| Total equity | $199M |
| Equity ÷ assets | 24.1% |
| Return on equity | -100.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.71 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -1151.4% in FY2025; revenue is hard to predict: its 80% range is ±71%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $16.1M (FY2025), total debt $71.9M. Experience: revenue down 40.6% on the year, down 58.1% a year over 4 years; operating margin -1151.4%, down from -679.6%. Soundness: equity 24.1% of assets, return on equity -100.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.7M and $21.8M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.3M to $24.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1151.4% against a -3.8% median; growth -40.6% against 13.7%.

Range logged 2026-09-29, receipt b0e430cab7d8fb6e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-06-15 ([filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926074067/0001104659-26-074067-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/0001104659-26-122367-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/0001104659-26-122362-index.htm)
- 8-K · filed 2026-11-02 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/0001104659-26-120915-index.htm)
- 8-K · filed 2026-09-29 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926111654/0001104659-26-111654-index.htm)
- 8-K · filed 2026-09-02 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926104463/0001104659-26-104463-index.htm)
- 10-Q · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087815/0001104659-26-087815-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001590560.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1590560

## Cite

POPS4, Edgar & Edgarette: uniQure N.V. (QURE) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/QURE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.